1-4 of 4
Martin Oft
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Free
Maria Lia Palomba, Paolo F. Caimi, Matthew Mei, Francisco Hernandez-Ilizaliturri, Geoffrey Shouse, Allison M. Winter, Greg Yedinak, David Mou, Nestor Huang, Anna Moua, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Naiyer Rizvi, Sherry Unabia, Peg Taylor, Jeffrey McLeroy, Matthew J Cortese
Journal: Blood
Blood (2024) 144 (Supplement 1): 3453.
https://doi.org/10.1182/blood-2024-202090
Published: 2024
Journal Articles

OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy

Free
Paul-Joseph Aspuria, Michael A Bauer, PhD, Sandro vivona, Rene de Waal Malefyt, Rob Kastelein, Martin Oft, Jan Emmerich, Deepti Rokkam, Steven E Kauder, PhD, Scott McCauley, Romina Riener, Rakesh Verma, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-143483
Published: 2020
Journal Articles

Pegilodecakin, a Pegylated Human IL-10 (AM0010), Enhances the Cytotoxicity of CAR-T Cells in Vitro and In Vivo

Free
Scott McCauley, Rakesh Verma, PhD, Martin Oft, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2058.
https://doi.org/10.1182/blood-2018-99-119359
Published: 2018
Journal Articles

No immunosurveillance in human IL-10R deficiency

Free
Martin Oft
Journal: Blood
Blood (2013) 122 (23): 3702–3703.
https://doi.org/10.1182/blood-2013-10-531657
Published: 2013